Does intensification of chemotherapy in anaplastic oligodendrogliomas still have a role?
作者信息
Soffietti Riccardo
机构信息
Department of Neuro-Oncology, University of Torino, Italy.
出版信息
Neuro Oncol. 2017 Oct 1;19(10):1292-1293. doi: 10.1093/neuonc/nox146.
Abstract
摘要
相似文献
1
Does intensification of chemotherapy in anaplastic oligodendrogliomas still have a role?间变性少突胶质细胞瘤化疗强化是否仍有作用？
Neuro Oncol. 2017 Oct 1;19(10):1292-1293. doi: 10.1093/neuonc/nox146.
2
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.间变性少突胶质细胞瘤患者化疗反应和生存的特定基因预测指标
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9. doi: 10.1093/jnci/90.19.1473.
3
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.新诊断间变性少突胶质细胞瘤和间变性少突星形细胞瘤患者放疗前及同步替莫唑胺的II期试验：RTOG BR0131
Neuro Oncol. 2009 Apr;11(2):167-75. doi: 10.1215/15228517-2008-073. Epub 2008 Sep 8.
4
Oligodendroglioma cell lines containing t(1;19)(q10;p10).含有 t(1;19)(q10;p10) 的少突胶质细胞瘤细胞系。
Neuro Oncol. 2010 Jul;12(7):745-55. doi: 10.1093/neuonc/noq031. Epub 2010 Apr 13.
5
Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas.1号染色体短臂和19号染色体长臂缺失在儿童少突胶质细胞瘤中罕见。
Acta Neuropathol. 2005 Apr;109(4):387-92. doi: 10.1007/s00401-004-0976-2. Epub 2005 Mar 1.
6
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.新诊断的纯性和混合性间变性少突胶质细胞瘤患者使用高剂量替莫唑胺的疗效及患者报告的结局：一项II期多中心研究
J Neurooncol. 2015 Mar;122(1):111-9. doi: 10.1007/s11060-014-1684-y. Epub 2014 Dec 23.
7
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.替莫唑胺耐药性少突胶质细胞瘤的挽救性PCV化疗
Neurology. 2004 Sep 14;63(5):904-6. doi: 10.1212/01.wnl.0000137049.65631.db.
8
Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.染色体 1 和 19 的三体性预示着伴有 1p/19q 缺失的间变性少突胶质细胞瘤更早复发。
Clin Cancer Res. 2009 Oct 15;15(20):6430-7. doi: 10.1158/1078-0432.CCR-09-0867. Epub 2009 Oct 6.
9
Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion.Nogo-A：少突胶质细胞瘤诊断的有用标志物，可用于鉴定 1p19q 联合缺失。
Hum Pathol. 2012 Mar;43(3):374-80. doi: 10.1016/j.humpath.2011.05.007. Epub 2011 Aug 10.
10
Anaplastic oligodendroglioma arising from the brain stem and featuring 1p/19q co-deletion.脑干起源的间变性少突胶质细胞瘤，具有 1p/19q 共缺失。
Neuropathology. 2014 Feb;34(1):32-8. doi: 10.1111/neup.12043. Epub 2013 May 27.
本文引用的文献
1
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.多中心二期研究：替莫唑胺联合大剂量化疗联合自体造血干细胞移植治疗新诊断的间变性少突胶质细胞瘤。
Neuro Oncol. 2017 Oct 1;19(10):1380-1390. doi: 10.1093/neuonc/nox086.
2
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.NOA - 04关于间变性胶质瘤序贯放化疗采用PCV或替莫唑胺的随机III期试验的长期分析。
Neuro Oncol. 2016 Nov;18(11):1529-1537. doi: 10.1093/neuonc/now133. Epub 2016 Jul 1.
3
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.2016 年世界卫生组织中枢神经系统肿瘤分类：概述。
Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.
4
Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.1p/19q 联合缺失与组织学特征对放化疗治疗间变性神经胶质瘤患者预后的影响。
Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):268-76. doi: 10.1016/j.ijrobp.2014.10.027.
5
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.新诊断的纯性和混合性间变性少突胶质细胞瘤患者使用高剂量替莫唑胺的疗效及患者报告的结局：一项II期多中心研究
J Neurooncol. 2015 Mar;122(1):111-9. doi: 10.1007/s11060-014-1684-y. Epub 2014 Dec 23.
6
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors.长期生存的间变性少突胶质细胞瘤和少突星形细胞瘤患者的健康相关生活质量和认知功能。
J Neurooncol. 2014 Jan;116(1):161-8. doi: 10.1007/s11060-013-1278-0. Epub 2013 Oct 26.
7
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.三期临床试验：放化疗治疗间变性少突胶质细胞瘤：RTOG9402 的长期结果。
J Clin Oncol. 2013 Jan 20;31(3):337-43. doi: 10.1200/JCO.2012.43.2674. Epub 2012 Oct 15.
8
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.替莫唑胺辅助治疗新诊断的间变性少突胶质细胞瘤：欧洲癌症研究与治疗组织脑肿瘤研究组 26951 号研究的长期随访。
J Clin Oncol. 2013 Jan 20;31(3):344-50. doi: 10.1200/JCO.2012.43.2229. Epub 2012 Oct 15.
9
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.国际回顾性研究纳入了超过 1000 例成人弥漫性少突胶质细胞瘤患者。
Neuro Oncol. 2011 Jun;13(6):649-59. doi: 10.1093/neuonc/nor040.
10
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.一项关于强化化疗单独作为新诊断间变性少突胶质细胞瘤初始治疗的II期研究：中期分析
J Neurooncol. 2008 Sep;89(2):187-93. doi: 10.1007/s11060-008-9603-8. Epub 2008 May 6.
Zotero 插件